New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
12:18 EDTT, PRAN, NDZ, TEVA, MNTA, MYL, MUOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday in the last trading day of the first quarter of the year. The disappointing Chicago purchasing managers' report was offset by dovish comments from Fed Chief Yellen, who said the the central bank’s "extraordinary" aid will last for "some time.” ECONOMIC EVENTS: In the U.S., the Chicago PMI business barometer index came in at 55.9, versus the consensus forecast for a 59.0 reading. In Europe, the annual inflation rate across the 18-country eurozone fell for the third consecutive month, slipping to 0.5% in March, compared to analysts' consensus forecast for a milder drop to 0.6%. COMPANY NEWS: Shares of AT&T (T) advanced early in the session after the company's board of directors authorized the repurchase of up to 300M shares, or about 6% of its common shares outstanding. The company also noted it has 125M shares left under its buyback authorization that was issued in March of last year, but the stock had given up much of its early advance to be up fractionally near noon. MAJOR MOVERS: Among the notable gainers was Canada's Nordion (NDZ), which jumped 11% after the company agreed to be acquired by Sterigenics for $11.75 per share in cash shortly after Canada's government lifted its 25% limit on foreign investment in the company. Also higher following analyst commentary was Micron (MU), which rose nearly 8% amid notes in its defense from Stifel and Pacific Crest, as well as broad-based strength in technology stocks that have recently pulled back. Among the noteworthy losers were Momenta Pharmaceuticals (MNTA), which dropped 15%, and Mylan (MYL), which slipped over 1%, after the Supreme Court agreed to hear an appeal by Teva (TEVA) of a court ruling that would enable generic versions of its multiple sclerosis drug, Copaxone, to be sold in May. Also lower were shares of Prana Biotechnology (PRAN), which plunged over 70% after its clinical study of a drug being tested as a treatment of Alzheimer's Disease did not hit its primary endpoint. INDEXES: Near midday, the Dow was up 118.43, or 0.73%, to 16,441.49, the Nasdaq was up 52.48, or 1.26%, to 4,208.23, and the S&P 500 was up 14.56, or 0.78%, to 1,872.18.
News For T;PRAN;NDZ;TEVA;MNTA;MYL;MU From The Last 14 Days
Check below for free stories on T;PRAN;NDZ;TEVA;MNTA;MYL;MU the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 10, 2014
14:25 EDTTEVATeva Canada announces launch of generic version of Cipralex
Subscribe for More Information
10:44 EDTMUMicron mentioned positively at Raymond James
07:02 EDTMYLMylan to acquire U.S. rights to Arixtra injection from Aspen
Mylan's subsidiary Mylan Ireland Limited has entered into an agreement to acquire the U.S. commercialization, marketing and intellectual property rights relating to Arixtra Injection and the authorized generic of Arixtra from Aspen Global Incorporated. Arixtra is indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing hip fracture surgery. Mylan already is selling Arixtra in the U.S. through an interim distribution arrangement with Aspen and Apotex is currently selling the AG of Arixtra, which will be transitioning to Mylan Institutional by year end.
September 9, 2014
14:51 EDTTApple announces iPhone 6, 6 Plus with Retina HD, Apple Pay
Apple announced iPhone 6 and iPhone 6 Plus, featuring two new models with 4.7-inch and 5.5-inch Retina HD displays. The new iPhones feature a unibody enclosure of anodized aluminum that conforms with the shaped glass of the display. iPhone 6 and iPhone 6 Plus include the Apple-designed A8 chip with second generation 64-bit desktop-class architecture for fast performance and power efficiency. Both models include the M8 motion coprocessor that gathers motion data from the accelerometer, gyroscope, compass and the new barometer. iPhone 6 and iPhone 6 Plus introduce Apple Pay, a new way to securely pay for physical goods and services in stores or apps. Users can pay securely in stores by holding the phone near the contactless reader while keeping a finger on Touch ID. The iSight camera gets better with a new sensor featuring Focus Pixels for faster autofocus and iPhone 6 Plus users will also benefit from optical image stabilization technology that compensates for hand shake in low light and works with iOS 8 to reduce subject motion. With faster LTE download speeds of up to 150 Mbps, iPhone 6 and iPhone 6 Plus users can browse, download and stream content faster. The new iPhones also support voice calls over LTE, or VoLTE, as well as Wi-Fi calling. iPhone 6 comes in gold, silver or space gray, and will be available in the U.S. for a suggested retail price of $199 for the 16GB model, $299 for the 64GB model and 128GB model for $399 with a two-year contract. iPhone 6 Plus comes in gold, silver or space gray, and will be available in the US for a suggested retail price of $299 for the 16GB model, $399 for the 64GB model and $499 for the new 128GB model with a two-year contract. Both models will be available from the Apple Online Store, Apple’s retail stores, and through AT&T (T), Sprint (S), T-Mobile (TMUS), Verizon Wireless (VZ), additional carriers and select Apple Authorized Resellers. iPhone 6 and iPhone 6 Plus will be available in the US, Australia, Canada, France, Germany, Hong Kong, Japan, Puerto Rico, Singapore and the UK beginning on Friday, September 19, and customers can pre-order both models beginning on Friday, September 12.
07:29 EDTTUBM Canon to hold a summit
Subscribe for More Information
07:22 EDTMURaymond James to hold a conference
North American Equities Conference to be held in London, England on September 9.
07:17 EDTTThe Wireless Association to hold a conference
Subscribe for More Information
07:11 EDTTUBM Tech to hold a conference
Subscribe for More Information
06:42 EDTMYLLew expects to make decision on combating inversion deals soon, NY Times reports
Subscribe for More Information
06:03 EDTTTelefonica to trial AT&T's connected home technology in Europe
AT&T (T) and Telefonica (TEF) last night announced plans for a limited trial of AT&T's home security and automation service in Europe. By licensing the AT&T Digital Life platform, Telefonica can offer trial users a wireless home automation platform all managed through an easy-to-use, web-based user interface. AT&T independently owns its platform, allowing for others to license a turnkey solution. AT&T Digital Life is an IP-based, all wireless, home security, smart automation and energy management solution, all contained in an easy-to-use mobile app. Telefonica is the first company to license AT&T's Digital Life platform.
05:16 EDTTSprint announces improved phone-trade in program, price match guarantee
Subscribe for More Information
September 8, 2014
12:40 EDTTEVAFTC sues AbbVie over blocking of AndroGel generics
The Federal Trade Commission has filed a complaint in federal district court charging several pharmaceutical companies with "illegally blocking American consumers’ access to lower-cost versions of the blockbuster drug AndroGel." The FTC's complaint alleges that AbbVie (ABBV) and its partner Besins Healthcare filed baseless patent infringement lawsuits against potential generic competitors to delay the introduction of lower-priced versions of the testosterone replacement drug AndroGel. While the lawsuits were pending, AbbVie then entered into an anticompetitive pay-for-delay settlement agreement with Teva Pharmaceuticals (TEVA) to further delay generic drug competition, the FTC claims. Reference Link
11:05 EDTMYLOptions with increasing implied volatility
Options with increasing implied volatility: NPSP GILD VNET AVNR GTAT YHOO RHT VRTX SDRL COV MYL
10:51 EDTTAT&T U-verse TV, Rural Media Group reach distribution agreement
Subscribe for More Information
10:04 EDTMYLMylan calls active on activist investor speculation
Subscribe for More Information
09:57 EDTMYLRumor: Mylan moves up on activist investor speculation
Subscribe for More Information
09:27 EDTMNTA, MYL, TEVALeerink biotech analyst holds a luncheon meeting with a conference call
Biotech Analyst Schwartz provides an update on key trends and controversies for marketed MS therapies and discusses new data presented at ACTRIMS-ECTRIMS at a Luncheon Meeting with an Analyst/Industry conference call to be held in Boston on September 11 at 12:15 pm.
08:32 EDTMNTAMomenta Pharma exercises option to acquire antibody program from AnaptysBio
AnaptysBio announced that Momenta Pharma has exercised its option to acquire a novel antibody program from AnaptysBio. Upon payment of an option exercise fee to AnaptysBio, Momenta has received worldwide rights to therapeutic antibodies against a target selected based upon the anti-inflammatory effects of IVIg. The aforementioned option right was granted by AnaptysBio to Momenta under an agreement signed between the companies in December 2013.
08:02 EDTTEVATeva completes Reslizumab Phase III program
Subscribe for More Information
07:03 EDTMYLMylan annoucnes court grants summary judgment in favor of company
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use